Vibeke Strand1, Iain McInnes2, Philip Mease3, Peter Nash4, Howard Thom5, Chrysostomos Kalyvas6, Matthias Hunger7, Kunal Gandhi8, Luminita Pricop8, Steffen Jugl9, Ernest Choy10. 1. Biopharmaceutical Consultant, 306 Ramona Road, Portola Valley, CA 94028, USA. 2. Institute of Infection, Immunity & Inflammation, College of Medical, Veterinary & Life Sciences, University of Glasgow, Sir Graeme Davies Building, 120 University Place, Glasgow, G12 8TA, UK. 3. Swedish Medical Center & University of Washington, Department of Medicine, 601 Broadway, Suite 600, Seattle, WA 98122, USA. 4. Department of Medicine, University of Queensland, Brisbane, QLD 4072, Australia. 5. Bristol Medical School, Population Health Sciences, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK. 6. Mapi, an ICON plc company, De Molen 84, 3995 AX, Houten, Netherlands (address at the time that the study was conducted). 7. Mapi, an ICON plc company, Konrad-Zuse-Platz 11, 81829 Munich, Germany. 8. Immunology & Dermatology Franchise, Novartis Pharmaceuticals Corporation, One Health Plaza, Building 337, B04.3B, East Hanover, NJ, USA. 9. Global Patient Access Immunology, Hepatology & Dermatology, Novartis Pharma AG, Postfach, Basel, CH-4002, Switzerland. 10. CREATE Centre, Section of Rheumatology - Division of Infection & Immunity, Cardiff University School of Medicine, Tenovus Building, Heath Park Campus, Cardiff, CF14 4XN, UK.
Abstract
Aim: To compare secukinumab with infliximab in biologic-naive patients with psoriatic arthritis using matching-adjusted indirect comparison. Patients & methods: Individual patient baseline data for secukinumab were matched to published aggregate data for infliximab by key baseline characteristics, with matching weights determined by logistic regression, and used to recalculate American College of Rheumatology (ACR) responses for secukinumab, for comparison with infliximab. Results: There were no differences in outcomes between secukinumab and infliximab at weeks 6/8 and 14/16. At weeks 24 and 54/52, ACR 20 responses were higher with secukinumab 150 mg than infliximab. At week 54/52, ACR 20/50 responses were higher for secukinumab 300 mg than infliximab. Conclusion: In the mid to long term, patients receiving secukinumab were more likely to achieve ACR 20/50 responses than those receiving infliximab.
Aim: To compare secukinumab with infliximab in biologic-naive patients with psoriatic arthritis using matching-adjusted indirect comparison. Patients & methods: Individual patient baseline data for secukinumab were matched to published aggregate data for infliximab by key baseline characteristics, with matching weights determined by logistic regression, and used to recalculate American College of Rheumatology (ACR) responses for secukinumab, for comparison with infliximab. Results: There were no differences in outcomes between secukinumab and infliximab at weeks 6/8 and 14/16. At weeks 24 and 54/52, ACR 20 responses were higher with secukinumab 150 mg than infliximab. At week 54/52, ACR 20/50 responses were higher for secukinumab 300 mg than infliximab. Conclusion: In the mid to long term, patients receiving secukinumab were more likely to achieve ACR 20/50 responses than those receiving infliximab.
Authors: Amir Haddad; Tal Gazitt; Ilan Feldhamer; Joy Feld; Arnon Dov Cohen; Idit Lavi; Faten Tatour; Irena Bergman; Devy Zisman Journal: Arthritis Res Ther Date: 2021-01-29 Impact factor: 5.156
Authors: B Fautrel; B Zhu; P C Taylor; M van de Laar; P Emery; F De Leonardis; C L Kannowski; C Nicolay; Z Kadziola; I De La Torre; R Fleischmann Journal: RMD Open Date: 2020-04